🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
Trackers Drugs Comparisons API
Trackers› Clinical trials› Dublin
Clinical trial register · Ireland

Clinical Trials in Dublin, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Ireland and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Alert me on this filter Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 614 matching records held by the registry are in this view. Synced 25 Sep 2026, 03:15 UTC
614
Studies in scope
all four open statuses
320
Recruiting now
open to new participants
179
Lead sponsors
across recruiting studies
37
Irish site locations
across all listed studies
Phase mix of the 320 recruiting studies
Phase 3 96 Not applicable 79 Observational 76 Phase 2 29 Phase 1/2 20 Other 20
Narrow the register Reset
Matches title, registry number, sponsor, intervention and condition.
Recruitment status
Phase
Lead sponsor
Merck Sharp & Dohme LLC 35 University College Dublin 21 Royal College of Surgeons, Ireland 18 AbbVie 16 Bristol-Myers Squibb 14
Site location
Dublin 482 Cork 169 Galway 124 Limerick 56 Waterford 51
All 37 locations
Target enrolment
to

Trials with a site in Dublin

482 of 614 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Irish sites
Start
Active, closed
A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy
NCT06821542 Chronic Graft-versus-host-disease
DrugINCA034176
Incyte Corporation
Phase 3
9
Dublin
2025-06-04
Recruiting
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
NCT06952504 Endometrial Cancer
DrugsSacituzumab tirumotecan·Cisplatin·Carboplatin·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
1,123
Dublin, Cork
2025-05-22
Recruiting
Long-term Study Evaluating Joint Health in People With Haemophilia A Receiving Real-world Prophylactic Treatment With Efanesoctocog Alfa
NCT06940830 Hemophilia A
DrugEfanesoctocog alfa
Swedish Orphan Biovitrum
Phase 4
250
Dublin
2025-05-21
Recruiting
The Lung Health Check Pilot
NCT07099027 Non-Small Cell Lung Cancer
Royal College of Surgeons, Ireland
Not applicable
2,183
Dublin
2025-05-19
Recruiting
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
NCT06925737 Prostate Cancer, Prostatic Neoplasms
DrugsIfinatamab Deruxtecan·Prednisone·Paclitaxel
Merck Sharp & Dohme LLC
Phase 3
1,440
Dublin, Cork
2025-05-13
Recruiting
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
NCT06563895 Amyloidosis, Amyloid Cardiomyopathy, Transthyretin Amyloidosis, Cardiomyopathies
DrugAcoramidis
Eidos Therapeutics, a BridgeBio company
Phase 3
587
Dublin
2025-05-12
Recruiting
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
NCT06499285 Myelodysplastic Syndromes
DrugElritercept
Takeda
Phase 3
225
Cork, Dublin, Limerick
2025-05-06
Recruiting
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
NCT06881784 NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer, NSCLC, NSCLC (Non-small Cell Lung Carcinoma)
DrugsPemetrexed·Paclitaxel
Revolution Medicines, Inc.
Phase 3
590
Cork, Dublin, Galway
2025-05-06
Recruiting
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
NCT06652438 Acute Myeloid Leukemia, Adult
DrugRevumenib
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 3
448
Cork, Dublin, Galway, Waterford
2025-05-05
Recruiting
WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)
NCT06967805 Idiopathic Pulmonary Fibrosis
Mediar Therapeutics
Phase 2
164
Abbotstown, Drogheda, Dublin, Letterkenny
2025-05-05
Active, closed
A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease (SCD)
NCT06924970 Sickle Cell Disease
DrugTebapivat
Agios Pharmaceuticals, Inc.
Phase 2
59
Dublin
2025-05-01
Recruiting
PRospective phenotypIng and Multi-omic Endotyping of Progressive Pulmonary Fibrosis
NCT06855329 Progressive Pulmonary Fibrosis, Interstitial Lung Disease
University of Massachusetts, Worcester
Observational
500
Dublin
2025-05-01
Recruiting
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
NCT06875310 Carcinoma, Non-Small-Cell Lung
DrugsAdagrasib·Pemetrexed·Cisplatin·Carboplatin
Mirati Therapeutics Inc.
Phase 3
630
Cork, Dublin
2025-04-24
Recruiting
Single vs. Multiple Fraction Trial of Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastases/Progression
NCT05784428 Oligometastatic Disease, Oligoprogression, Toxicity Due to Radiotherapy, Quality of Life
Robert Olson
Not applicable
598
Galway, Dublin, Cork, Waterford
2025-04-16
By invitation
A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma Treatment
NCT06848088 Melanoma
DrugsFianlimab·Cemiplimab
Regeneron Pharmaceuticals
Phase 2
48
Dublin
2025-04-14
Recruiting
EXtubation Related Complications - the EXTUBE Study (EXTUBE)
NCT06442930 Extubation
University Health Network, Toronto
Observational
3,000
Castlebar, Cork, Dublin, Galway, Waterford
2025-04-14
Recruiting
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
NCT06890884 Lymphoma, Large B-Cell, Diffuse
DrugsRituximab Biosimilar·Zilovertamab vedotin·Polatuzumab Vedotin·Prednisolone
Merck Sharp & Dohme LLC
Phase 2
594
Dublin, Limerick
2025-04-11
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
NCT06868277 Carcinoma, Non-Small Cell Lung
DrugsRilvegostomig·Pembrolizumab
AstraZeneca
Phase 3
830
Cork, Dublin, Galway
2025-04-10
Recruiting
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
NCT06824467 Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
DrugsSteroid mouthwash (dexamethasone·Equivalent)·Acetaminophen·Sacituzumab tirumotecan
Merck Sharp & Dohme LLC
Phase 3
770
Dublin
2025-04-09
Active, closed
Study of Bitopertin in Participants With EPP or XLP (APOLLO)
NCT06910358 Erythropoietic Protoporphyria (EPP), X-Linked Protoporphyria (XLP)
DrugDISC-1459
Disc Medicine, Inc
Phase 3
183
Dublin
2025-04-04
Recruiting
A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.
NCT06898450 Advanced Solid Tumors Cancer, MSI-H Cancer
Nimbus Wadjet, Inc.
Phase 1/2
134
Dublin
2025-03-31
Recruiting
Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment
NCT06750289 Eosinophilic Asthma
AstraZeneca
Phase 3
400
Ballinasloe, Cork, Dublin, Moneymore
2025-03-28
Active, closed
Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)
NCT06726265 Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
DrugsPemetrexed·Cisplatin·Carboplatin·Pembrolizumab
Immutep S.A.S.
Phase 3
756
Cork, Dublin
2025-03-21
Recruiting
Assessing Intellectual and Motor Outcomes in High-risk Infants
NCT06857539 Cerebral Palsy, Cerebral Palsy (CP), Cerebral Palsy Children, High-risk Infants
University College Cork
Observational
600
Cork, Dublin
2025-03-21
Active, closed
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
NCT06764485 Metastatic Castration-resistant Prostate Cancer
DrugsAbiraterone·Enzalutamide·Paclitaxel
Celgene
Phase 3
960
Cork, Dublin
2025-03-13
Recruiting
Laparoscopic-Assisted Transversus Abdominus Plane Block Versus Intraperitoneal Irrigation of Local Anesthetic for Patients Undergoing Laparoscopic Cholecystectomy
NCT06714279 Laparoscopic Cholecystectomy, TAP Block, Local Anesthetic
Royal College of Surgeons, Ireland
Phase 1
144
Dublin
2025-03-12
Not yet open
An Educational Intervention to Improve the Success of Intubation in Newborns Using a Video Laryngoscope by Reducing the Time the Procedure Takes.
NCT06898801 Respiratory Distress Syndrome, Newborn, Endotracheal Intubation, Neonatal Intubation Performance, Prematurity
University College Dublin
Not applicable
140
Dublin
2025-03
Recruiting
A 3-part Study of SYX-5219 in Healthy Volunteers and Participants With Atopic Dermatitis
NCT07558668 Moderate to Severe Atopic Dermatitis
Sitryx Therapeutics Ltd
Phase 1
149
Dublin
2025-02-26
Active, closed
A Real-World Study to Gain Clinical Insights Into Faricimab (FaReal Study)
NCT06680817 Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
DrugFaricimab
Hoffmann-La Roche
Observational
850
Dublin, Limerick, Waterford
2025-02-05
By invitation
Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE
NCT06679881 Hereditary Angioedema (HAE)
DrugDeucrictibant
Pharvaris Netherlands B.V.
Phase 3
170
Dublin
2025-02-01
Recruiting
An Ex-US Study to Assess Treatment Persistence With Risankizumab in Adult Participants With Psoriatic Arthritis
NCT06764693 Psoriatic Arthritis
AbbVie
Observational
1,200
Dublin, Elm Park, Tralee, Cork
2025-01-31
Recruiting
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
NCT06788990 Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
DrugsFicerafusp alfa·Pembrolizumab
Bicara Therapeutics
Phase 2/3
650
Cork, Dublin
2025-01-28
Recruiting
Inter- and Intraindividual Variability of the Acute Glucose Response to Exercise in Healthy Adults and People Living With Type 1 Diabetes: A Cross-over Replicate Trial
NCT07209930 Exercise, Healthy Participants, Glucose Variability, Type 1 Diabetes (T1D)
University College Dublin
Not applicable
24
Dublin
2025-01-28
Recruiting
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
NCT06100289 Ulcerative Colitis, Crohn's Disease
DrugVedolizumab
Takeda
Phase 3
70
Dublin
2025-01-22
Recruiting
A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
NCT06585774 Chronic Graft-versus-host-disease
DrugINCA034176
Incyte Corporation
Phase 3
240
Dublin
2025-01-21
Recruiting
A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.
NCT06284317 Non Small Cell Lung Cancer
ETOP IBCSG Partners Foundation
Phase 3
290
Dublin
2025-01-15
Active, closed
A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome
NCT06684847 Primary Sjogrens Disease
DrugEfgartigimod PH20
argenx
Phase 3
631
Dublin
2025-01-15
Not yet open
Rehab in Mild Stable DCM: Feasibility RCT Comparing Structured Rehabilitation to Clinical Surveillance
NCT06781658 Degenerative Cervical Myelopathy
Royal College of Surgeons, Ireland
Not applicable
24
Dublin
2025-01-13
Active, closed
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
NCT06760637 Breast Cancer
DrugsPF-07220060·Ribociclib·Abemaciclib·Palbociclib
Pfizer
Phase 3
1,035
Dublin
2025-01-06
Recruiting
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
NCT06227910 Crohn's Disease
DrugsVedolizumab·Upadacitinib
Takeda
Phase 3
396
Dublin
2025-01-02
Not yet open
AUGUR-AI - Indocyanine Green Fluorescence Angiography Representer
NCT06708819 Colorectal Surgery, Colorectal Resection, Anastomosis, Surgical, Fluorescence Guided Surgery
Mater Misericordiae University Hospital
Observational
300
Dublin
2025-01
Active, closed
Exoskeleton Training for Spinal Cord Injury Neuropathic Pain (ExSCIP)
NCT06463418 Traumatic Spinal Cord Injury
University College Dublin
Not applicable
40
Dublin
2024-12-20
Recruiting
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
NCT06679101 Multiple Myeloma, Newly Diagnosed Multiple Myeloma
DrugsBelantamab mafodotin·Daratumumab·Lenalidomide·Dexamethasone
GlaxoSmithKline
Phase 3
520
Dublin, Galway, Waterford
2024-12-16
Active, closed
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
NCT06500455 Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Digestive System Carcinoma, Metastatic Lung Non-Small Cell Carcinoma
NRG Oncology
Phase 3
274
Dublin, Galway, Cork
2024-12-12
Recruiting
A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide in Adolescents (12 - 18 Years of Age) With Achondroplasia.
NCT06732895 Achondroplasia
DrugNavepegritide
Ascendis Pharma A/S
Phase 2
24
Dublin
2024-12-10
Active, closed
Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE
NCT06669754 Hereditary Angioedema (HAE)
DrugDeucrictibant
Pharvaris Netherlands B.V.
Phase 3
81
Dublin
2024-12-01
Recruiting
SYMPHONY™ OCT System for Instabilities of the Upper Thoracic and Cervical Spine
NCT06816862 Cervical Instabilities Spine, Spine; Instability
University College Dublin
Observational
35
Dublin
2024-12-01
Active, closed
Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)
NCT06635824 PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC
DrugsPembrolizumab·Paclitaxel
Genmab
Phase 3
191
Cork, Dublin, Limerick, Waterford
2024-11-25
Recruiting
Measurement and Impact of Physical Impairment in Amyotrophic Lateral Sclerosis: Use of Digital Technologies - A Precision ALS Project
NCT06820008 Amyotrophic Lateral Sclerosis, Motor Neurone Disease
University of Dublin, Trinity College
Observational
60
Dublin
2024-11-21
Recruiting
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
NCT06690775 Epithelial Ovarian Cancer, Primary Peritoneal, Fallopian Tube Cancer, Endometrioid Ovarian Cancer
DrugsPegfilgrastim·TORL-1-23
TORL Biotherapeutics, LLC
Phase 2
230
Dublin
2024-11-20
Active, closed
A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)
NCT06422884 Idiopathic Pulmonary Fibrosis, Progressive Fibrosing Interstitial Lung Disease
Endeavor Biomedicines, Inc.
Phase 2
213
Dublin, Cork
2024-11-15
Active, closed
A Study on Safety and Effectiveness of Long-term Treatment With Vamorolone in Boys With Duchenne Muscular Dystrophy
NCT06713135 Duchenne Muscular Dystrophy
DrugVamorolone
Santhera Pharmaceuticals
Phase 4
80
Dublin
2024-11-10
Recruiting
A Study of Vonicog Alfa (rVWF) in Children With Severe Von Willebrand Disease (vWD)
NCT05582993 Von Willebrand Disease (VWD)
DrugAdvate
Takeda
Phase 3
24
Dublin
2024-11-06
Recruiting
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
NCT06623422 Carcinoma, Non-Small-Cell Lung
DrugsIntismeran autogene·Gemcitabine·Pemetrexed·Cisplatin
Merck Sharp & Dohme LLC
Phase 3
680
Cork, Dublin
2024-10-21
Recruiting
A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia
NCT06544499 Primary Immune Thrombocytopenia (ITP)
DrugEfgartigimod
argenx
Phase 3
69
Dublin
2024-10-18
Active, closed
A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS)
NCT06643481 Amyotrophic Lateral Sclerosis (ALS)
DrugVHB937
Novartis Pharmaceuticals
Phase 2
251
Dublin
2024-10-17
Recruiting
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
NCT06598943 Ulcerative Colitis, Ulcerative Colitis Chronic
DrugMirikizumab
Eli Lilly and Company
Phase 2
143
Dublin
2024-10-10
Recruiting
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
NCT06561386 Non-small Cell Lung Cancer
DrugsRelatlimab·Nivolumab·Pemetrexed·Cisplatin
Bristol-Myers Squibb
Phase 3
1,000
Dublin
2024-10-07
Recruiting
Efficacy of INM004 in Children With STEC-HUS
NCT06389474 Hemolytic-Uremic Syndrome
Inmunova S.A.
Phase 3
220
Dublin
2024-10-05
Active, closed
Group-based Resistance Training for Adults With Down Syndrome
NCT07347912 Down Syndrome, Healthy Aging, Resistance Training
Saint John of God Intellectual Disability Services - Dublin South East
Not applicable
36
Dublin
2024-10-01
Recruiting
ENVELOP: Wound Care Following Pilonidal Sinus Surgery
NCT06647290 Pilonidal Sinus, Wound Healing
Royal College of Surgeons, Ireland
Not applicable
200
Castlebar, Dublin, Kilkenny, Limerick, Tullamore, Waterford
2024-10-01
Recruiting
A Prospective Study of the Genomic Landscape of Central Nervous System Disease Secondary to Breast Cancer Utilising Cell-free DNA Derived From Cerebrospinal Fluid (CSF)
NCT07503704 Breast Cancer
Royal College of Surgeons, Ireland
Observational
69
Dublin
2024-10-01
Recruiting
A Study in Adults to Learn About Inherited Alpha-1 Antitrypsin Deficiency (AATD) and AATD Related Liver Problems
NCT06512454 Alpha1-Antitrypsin Deficiency
Takeda
Observational
500
Dublin
2024-09-25
Recruiting
Implementation of a Standardized Algorithm for Coronary Calcification With Plaque Modification
NCT06678594 Myocardial Ischaemia, Severely Calcified Coronary Stenoses, Coronary Calcification
Royal College of Surgeons, Ireland
Observational
500
Dublin
2024-09-24
Recruiting
A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma
NCT06140524 Monoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Multiple Myeloma (SMM)
DrugLinvoseltamab
Regeneron Pharmaceuticals
Phase 2
116
Galway, Cork, Dublin
2024-09-16
Recruiting
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
NCT06586515 Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer
DrugsLeucovorin·Irinotecan·Nab-paclitaxel·Oxaliplatin
Eli Lilly and Company
Phase 1
630
Dublin
2024-09-12
Recruiting
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
NCT06548542 Crohn's Disease
DrugsTrosunilimab·Lutikizumab·Risankizumab
AbbVie
Phase 2
540
Letterkenny, Ballinasloe, Drogheda, Mullingar, Dublin
2024-09-04
Recruiting
Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)
NCT06274801 Pulmonary Arterial Hypertension
DrugSeralutinib
Gossamer Bio USA, Inc.
Phase 3
330
Dublin
2024-09-03
Active, closed
Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)
NCT06564142 Immunoglobulin A Nephropathy
DrugPovetacicept
Alpine Immune Sciences Inc, A Subsidiary of Vertex
Phase 3
605
Cork, Dublin, Galway, Waterford
2024-08-30
By invitation
Impact of Aromatherapy on Wellbeing and Relaxation in Gynae Oncology Patients Post Treatment
NCT06590077 Stress, Wellbeing, Relaxation
University of Dublin, Trinity College
Not applicable
40
Dublin
2024-08-19
By invitation
Sleep Well At Night
NCT07068971 Sleep Disturbance in Advanced Cancer
Our Lady's Hospice and Care Services
Not applicable
30
Dublin
2024-08-19
Recruiting
Prophylactic Surfactant by Thin Endotracheal Catheter for Preterm Infants At Birth: the ProTeCt Trial
NCT06557551 Infant, Newborn, Diseases, Prematurity, Prematurity; Extreme, Respiratory Distress Syndrome in Premature Infant
University College Dublin
Not applicable
164
Dublin
2024-08-19
Recruiting
Real World Data Collection on the Synergy Disc
NCT06383949 Cervical Degenerative Disc Disease
Synergy Spine Solutions
Observational
50
Dublin
2024-08-06
Active, closed
A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression
NCT06365853 Recurrent Ovarian Cancer, Folate Receptor-Alpha Positive
DrugMirvetuximab Soravtansine
AbbVie
Phase 2
108
Dublin
2024-07-29
Active, closed
A Phase 2 Clinical Trial to Evaluate Efficacy, Safety, and Tolerability of Navepegritide in Combination With Lonapegsomatropin in Children With Achondroplasia
NCT06433557 Achondroplasia
Ascendis Pharma Growth Disorders A/S
Phase 2
22
Dublin
2024-07-26
Active, closed
A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
NCT06459180 Cervical Cancer
DrugsTisotumab Vedotin·Vinorelbine·Topotecan·Sacituzumab tirumotecan
Merck Sharp & Dohme LLC
Phase 3
686
Cork, Dublin
2024-07-24
Recruiting
TreatHSP Platform: Adaptive Natural History Platform for Ataxias, HSPs, and Spastic Ataxias
NCT07798674 Hereditary Spastic Paraplegia, Spastic Ataxia
Heidelberg University
Observational
4,000
Dublin
2024-07-16
Recruiting
Fibrosis Lessens After Metabolic Surgery
NCT06374875 Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Non-Alcoholic Fatty Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis (MASH), Liver Fibrosis
The Cleveland Clinic
Phase 4
120
Dublin
2024-07-11
Recruiting
CONDUIT™ Anterior Lumbar Interbody Fusion (ALIF) Cage System in Lumbar Degenerative Disease
NCT06940453 Lumbar Degenerative Disease
University College Dublin
Observational
35
Dublin
2024-06-28
Active, closed
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
NCT06468228 Hidradenitis Suppurativa
DrugLutikizumab
AbbVie
Phase 3
1,400
Drogheda, Cork, Dublin
2024-06-27
Recruiting
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
NCT06393374 Triple-Negative Breast Cancer
DrugsSacituzumab tirumotecan·Capecitabine·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
1,530
Cork, Dublin, Galway
2024-06-24
Active, closed
Long-term, Open-label Study of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency Emphysema
NCT05897424 Alpha 1-Antitrypsin Deficiency, Emphysema
Sanofi
Phase 2
185
Dublin
2024-06-20
Recruiting
A Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD)
NCT06389877 Alpha 1-Antitrypsin Deficiency
Beam Therapeutics Inc.
Phase 1/2
106
Dublin
2024-06-19
Recruiting
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
NCT06422143 Non-small Cell Lung Cancer, NSCLC
DrugsSac-TMT·Nab-paclitaxel·Carboplatin·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
851
Dublin
2024-06-10
Recruiting
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
NCT06430801 Crohn's Disease
DrugTulisokibart
Merck Sharp & Dohme LLC
Phase 3
1,200
Dublin
2024-06-05
Active, closed
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab
NCT06211036 Extensive-Stage Small-Cell Lung Cancer, Small-Cell Lung Cancer
DrugsTarlatamab·Durvalumab
Amgen
Phase 3
563
Dublin
2024-06-05
Active, closed
The Effect of an Adhesive System on the Retention and Caries Prevention for Fissure Sealants in Permanent Molars
NCT06608563 Dental Caries, Fissure Sealant
University of Dublin, Trinity College
Not applicable
100
Dublin
2024-06-05
Recruiting
Effect of L-PRF on Implant Stability and Marginal Bone Levels.
NCT06516263 Dental Implant, Implant Stability, Marginal Bone Levels, L-PRF
Dublin Dental University Hospital
Not applicable
50
Dublin
2024-06-01
By invitation
Prostate Cancer Awareness and Initiative for Screening in the European Union
NCT06424275 Prostate Cancer
European Association of Urology Research Foundation
Observational
20,000
Dublin
2024-06-01
Not yet open
Evaluating a Targeted Selective Speech, Language, and Communication Intervention at Scale - Protocol for the 'Happy Talk' Cluster Randomised Controlled Trial.
NCT06460090 Developmental Language Disorder and Language Impairment, Deprivation
University College Cork
Not applicable
840
Dublin, Galway, Wexford, Wicklow
2024-06
Active, closed
Cognition in Older Adults With Cancer Receiving Systemic Anti-Cancer Therapy
NCT07411105 Cancer, Older Adults (65 Years and Older), Cognition
Our Lady's Hospice and Care Services
Observational
30
Dublin
2024-05-21
Recruiting
VE303 for Prevention of Recurrent Clostridioides Difficile Infection
NCT06237452 Clostridium Difficile, Clostridium Difficile Infections, Clostridium Difficile Infection Recurrence, Clostridioides Difficile Infection
Vedanta Biosciences, Inc.
Phase 3
852
Dublin, Drogheda
2024-05-20
Recruiting
Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
NCT06353386 Prostatic Neoplasms, Castration-Resistant
DrugsFludrocortisone acetate·Cabazitaxel·Opevesostat·Olaparib
Merck Sharp & Dohme LLC
Phase 1/2
220
Dublin, Cork
2024-05-20
Active, closed
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
NCT06238622 Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
DrugNerandomilast
Boehringer Ingelheim
Phase 3
1,666
Dublin
2024-05-06
Recruiting
Exploring the Impact of a Multi-modal Nutritional Intervention in Patients Undergoing Chemotherapy for Pancreatic Cancer (FEED Trial)
NCT06149546 Pancreatic Cancer
Cancer Trials Ireland
Not applicable
70
Dublin
2024-05-01
By invitation
A Long-term Extension Study to Assess the Long-term Safety and Efficacy of Pegtibatinase Treatment in Participants ≥5 to ≤65 Years of Age With Classical Homocystinuria (HCU) (ENSEMBLE)
NCT06431893 Homocystinuria
DrugPegtibatinase
Travere Therapeutics, Inc.
Phase 3
100
Dublin
2024-04-30
Recruiting
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
NCT06319820 Non-Muscle Invasive Bladder Neoplasms
DrugGemcitabine
Janssen Research & Development, LLC
Phase 3
641
Cork, Dublin
2024-04-18
Recruiting
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
NCT06312176 Breast Neoplasms
DrugsLiposomal doxorubicin·Sacituzumab tirumotecan·Nab-paclitaxel·Capecitabine
Merck Sharp & Dohme LLC
Phase 3
1,200
Cork, Dublin
2024-04-14
Recruiting
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
NCT06330064 Recurrent or Metastatic Solid Tumors
DrugIfinatamab Deruxtecan
Daiichi Sankyo
Phase 1/2
680
Dublin, Cork, Galway
2024-04-10
Active, closed
An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS)
NCT06073132 Generalized Epidermolysis Bullosa Simplex
TWi Biotechnology, Inc.
Phase 2/3
80
Dublin
2024-04-04
Rows per page Showing 101–200 of 482
Previous 1 2 3 4 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Irish investigative site, filtered. Derived from ClinicalTrials.gov, U.S. National Library of Medicine. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-ireland/city/dublin?page=2

Query this register directly
GET /api/trials?country=ie&status=recruiting&phase=Phase+3&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Ireland and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 614 studies in total at the last sync on 25 Sep 2026, 03:15 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 482 of those studies with a site in Dublin.

How many clinical trials are recruiting in Dublin?

245 of the 482 studies on this page are recruiting new participants as of the 25 Sep 2026, 03:15 UTC sync. A further 19 have not yet opened recruitment, 203 are active but closed to new participants, and 15 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. Patients should discuss participation with their clinician. For trials across the wider EU, see the EU Clinical Trials Tracker.